Fig. 7

Expression of bmp2/4 at oral mesovesicle and lack of oral structures in Dorsomophin-treated larvae. a, b Expression of bmp2/4 at future perforation site in oral mesovesicle (arrowhead) at 24 hpf at 25 °C viewed left laterally (a) and dorsally (b). c Control 72-hpf larva having well-developed mouth on the left side. d Muscle fibers of oral musculature immunolabelled with anti-α smooth muscle actin antibody in untreated 72-hpf larva. e, f 72-hpf larva treated with Dorsomorphin reduced size of mouth as a pit (arrowhead in e) and absence of oral musculature (f). g, h Treated larva lacking mouth (g) and oral musculature (h). i A dose-dependent effect of Dorsomorphin on mouth opening treated from 24 to 30 hpf at 25 °C. m, mouth; om, oral musculature; 1, 2 pg, first and second primary gill; pp, preoral pit. Scale bar 100 μm for (a), (b) and the others